Bio-Rad Laboratories, Inc. reported a strong first quarter of 2022 with adjusted earnings per share (EPS) of $4.94, well above the Zacks Consensus Estimate by 76.4%. However, the company faced a GAAP loss of $112.57 per share and a 3.7% decline in revenues, totaling $700 million, despite slightly exceeding estimations. Looking ahead, Bio-Rad anticipates modest currency-neutral revenue growth of 1-2% and has reaffirmed its full-year guidance for 2022.
“Bio-Rad Laboratories, Inc. · posted · first-quarter 2022 adjusted earnings per share (EPS) · $4.94”
“Bio-Rad Laboratories, Inc. · surpassed · the Zacks Consensus Estimate · by 76.4%”
“Bio-Rad Laboratories, Inc. · recorded · GAAP loss · $112.57 per share”
“Bio-Rad Laboratories, Inc. · recorded · GAAP earnings · $32.38”
“Bio-Rad Laboratories, Inc. · reported · revenues · $700 million”
“Bio-Rad Laboratories, Inc. · surpassed · the Zacks Consensus Estimate for revenues · by 3.3%”
“Bio-Rad Laboratories, Inc. · experienced · revenues decline · 3.7%”
“Bio-Rad · anticipates · currency-neutral revenue growth · nearly 1-2%”
“Bio-Rad Laboratories · first-quarter revenues estimate · $678 million”
“Bio-Rad Laboratories · first-quarter earnings per share estimate · $2.80”
“Bio-Rad Laboratories, Inc. · posted · first-quarter 2022 adjusted earnings per share (EPS) · $4.94”
“Bio-Rad Laboratories, Inc. · surpassed · Zacks Consensus Estimate · 76.4%”